ChemotherapyFDA-approvedFirst-line
Gemcitabine
How it works
Gemcitabine is a nucleoside analog that interferes with DNA synthesis, causing cancer cells to die. It also triggers apoptosis in cancer cells.
Cancer types
Pancreatic Cancer— All patients
Lung Cancer— All patients
Efficacy
Studies show that gemcitabine can improve overall survival in patients with pancreatic cancer, with a median survival of approximately 5.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Gemcitabine and WEE1 Inhibitor Trial for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Gemcitabine, Dasatinib, and Erlotinib in Treating Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing Chemotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | preclinical | — | Source → |
| Gene BHLHE41 May Help Pancreatic Cancer Cells Respond Better to Treatment | Pancreatic Cancer | lab-study | — | Source → |
| New Compound Shows Promise in Treating Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining Camrelizumab with Gemcitabine and Paclitaxel in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The median overall survival was 14.0 months, and the median progression-free survival was 6.4 months. | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| IGF2BP2 helps cancer cells resist treatment in pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| OTUB1 linked to gemcitabine resistance in pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| New Nanoparticle Platform for Targeted Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| REG3A linked to gemcitabine resistance in pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Combining medications to treat advanced breast and ovarian cancer | Ovarian Cancer | phase-1 | There were 3 major responses (1CR, 2PR) at DL1, and 1 CR at DL-1. | Source → |
| Gemcitabine Resistance in Pancreatic Cancer: A New Target for Treatment | Pancreatic Cancer | lab-study | — | Source → |
| New Nanoparticles Help Deliver Cancer Treatment to Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine and Flurbiprofen May Help Kill Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Gold Nanoclusters Help Deliver Cancer Drug More Effectively | Breast Cancer | lab-study | The resultant Gem-AuNCs-BSA showed enhanced delivery of drug and therapeutic effects for the treatment of breast cancer and lung cancer with better efficacy than free Gemcitabine. | Source → |
| α-Asarone May Help Overcome Gemcitabine Resistance in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Bacteria in Pancreatic Tumors May Affect Treatment Effectiveness | Pancreatic Cancer | observational | High intratumoral bacterial abundance impaired aGC efficacy (DFS 9.4 vs 19.1 months, p < 0.001; OS 19.4 vs 34.0 months, p < 0.001), which was mitigated by postoperative ABT application (DFS 7.9 vs 12.4 months, p < 0.001, OS 15.2 vs 29.6 months, p < 0.001). | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Linked to Protein TSPAN15 | Pancreatic Cancer | lab-study | Venetoclax, a targeted inhibitor of TSPAN15, exhibits synergistic efficacy when combined with gemcitabine for treating PDAC both in vitro and in vivo. | Source → |
| New Approach to Treating Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Signature Predicts Response in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The Gem+ patients who received adjuvant gemcitabine had significantly better median disease-free survival (DFS) compared to the Gem- patients (NR until 72 months of follow-up vs 19.0 months); stratified hazard ratio [HR]: 0.19; 95% CI, 0.04-0.86; P = .032 | Source → |
| Gemcitabine May Help Overcome Resistance to Leukemia Treatment | Leukemia | lab-study | — | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| Combining Gemcitabine and AZD 1775 May Improve Treatment for Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining CHK1 Inhibitor with Gemcitabine May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Gemcitabine-resistant pancreatic cancer cells identified | Pancreatic Cancer | lab-study | Pharmacological inhibition of MAOB significantly suppressed proliferation and tumor growth in both mPDAC-R and human PDAC cell lines. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.